Cardiovascular pharmacogenomics
Copyright © 2013 Instituto Nacional de Cardiología Ignacio Chávez. Published by Masson Doyma México S.A. All rights reserved..
Cardiovascular disease remains a major cause of morbidity and mortality worldwide. Current medical practice takes into account information based on population studies and benefits observed in large populations or cohorts. However, individual patients present great differences in both toxicity and clinical efficacy that can be explained by variations in adherence, unknown drug to drug interactions and genetic variability. The latter seems to explain from 20% up to 95% of patient to patient variability. Treating patients with cardiovascular disorders faces the clinician with the challenge to include genomic analysis into daily practice. There are several examples within cardiovascular disease of treatments that can vary in toxicity or clinical usefulness based on genetic changes. One of the main factors affecting the efficacy of Clopidogrel is the phenotype associated with polymorphisms in the gene CYP 2C9. Furthermore, regarding oral anticoagulants, changes in CYP2C9 and VKORC1 play an important role in changing the clinical response to anticoagulation. When analyzing statin treatment, one of their main toxicities (myopathy) can be predicted by the SLCO1B1 polymorphism. The potential for prediction of toxicity and clinical efficacy from the use of genetic analysis warrants further studies aiming towards its inclusion in daily clinical practice.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2014 |
|---|---|
| Erschienen: |
2014 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:84 |
|---|---|
| Enthalten in: |
Archivos de cardiologia de Mexico - 84(2014), 1 vom: 17. Jan., Seite 25-31 |
| Sprache: |
Spanisch |
|---|
| Weiterer Titel: |
Farmacogenómica cardiovascular |
|---|
| Beteiligte Personen: |
Scibona, Paula [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 15.01.2015 Date Revised 02.12.2018 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.acmx.2013.11.003 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM236460404 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM236460404 | ||
| 003 | DE-627 | ||
| 005 | 20231224105623.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2014 xx |||||o 00| ||spa c | ||
| 024 | 7 | |a 10.1016/j.acmx.2013.11.003 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0788.xml |
| 035 | |a (DE-627)NLM236460404 | ||
| 035 | |a (NLM)24636047 | ||
| 035 | |a (PII)S1405-9940(14)00003-2 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a spa | ||
| 100 | 1 | |a Scibona, Paula |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Cardiovascular pharmacogenomics |
| 246 | 3 | 3 | |a Farmacogenómica cardiovascular |
| 264 | 1 | |c 2014 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 15.01.2015 | ||
| 500 | |a Date Revised 02.12.2018 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2013 Instituto Nacional de Cardiología Ignacio Chávez. Published by Masson Doyma México S.A. All rights reserved. | ||
| 520 | |a Cardiovascular disease remains a major cause of morbidity and mortality worldwide. Current medical practice takes into account information based on population studies and benefits observed in large populations or cohorts. However, individual patients present great differences in both toxicity and clinical efficacy that can be explained by variations in adherence, unknown drug to drug interactions and genetic variability. The latter seems to explain from 20% up to 95% of patient to patient variability. Treating patients with cardiovascular disorders faces the clinician with the challenge to include genomic analysis into daily practice. There are several examples within cardiovascular disease of treatments that can vary in toxicity or clinical usefulness based on genetic changes. One of the main factors affecting the efficacy of Clopidogrel is the phenotype associated with polymorphisms in the gene CYP 2C9. Furthermore, regarding oral anticoagulants, changes in CYP2C9 and VKORC1 play an important role in changing the clinical response to anticoagulation. When analyzing statin treatment, one of their main toxicities (myopathy) can be predicted by the SLCO1B1 polymorphism. The potential for prediction of toxicity and clinical efficacy from the use of genetic analysis warrants further studies aiming towards its inclusion in daily clinical practice | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Argentina | |
| 650 | 4 | |a Clopidogrel | |
| 650 | 4 | |a Estatinas | |
| 650 | 4 | |a Farmacogenómica | |
| 650 | 4 | |a Pharmacogenomic | |
| 650 | 4 | |a Polimorfismo | |
| 650 | 4 | |a Polymorphism | |
| 650 | 4 | |a Statin | |
| 650 | 4 | |a Warfarin | |
| 650 | 4 | |a Warfarina | |
| 650 | 7 | |a Anticoagulants |2 NLM | |
| 650 | 7 | |a Platelet Aggregation Inhibitors |2 NLM | |
| 650 | 7 | |a Clopidogrel |2 NLM | |
| 650 | 7 | |a A74586SNO7 |2 NLM | |
| 650 | 7 | |a Ticlopidine |2 NLM | |
| 650 | 7 | |a OM90ZUW7M1 |2 NLM | |
| 700 | 1 | |a Angriman, Federico |e verfasserin |4 aut | |
| 700 | 1 | |a Simonovich, Ventura |e verfasserin |4 aut | |
| 700 | 1 | |a Heller, Martina M |e verfasserin |4 aut | |
| 700 | 1 | |a Belloso, Waldo H |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Archivos de cardiologia de Mexico |d 2001 |g 84(2014), 1 vom: 17. Jan., Seite 25-31 |w (DE-627)NLM114616272 |x 1665-1731 |7 nnns |
| 773 | 1 | 8 | |g volume:84 |g year:2014 |g number:1 |g day:17 |g month:01 |g pages:25-31 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.acmx.2013.11.003 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 84 |j 2014 |e 1 |b 17 |c 01 |h 25-31 | ||